<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086786</url>
  </required_header>
  <id_info>
    <org_study_id>ROV-RISP-2011-02</org_study_id>
    <nct_id>NCT02086786</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia</brief_title>
  <acronym>PRISMA-2</acronym>
  <official_title>Multicenter, Open-label, Two-arm, Parallel-design, Repeat-dose Clinical Trial to Evaluate the PK, Safety, and Tolerability of Four Intramuscular Injections of Risperidone ISM® 75 mg, at 28 Day Intervals in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rovi Pharmaceuticals Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rovi Pharmaceuticals Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting
      formulation (in situ microparticle, ISM) of risperidone over four IM injections in the
      gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients
      with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, open-label, two-arm, parallel-design, repeat-dose clinical study
      designed to evaluate the PK, safety, and tolerability of Risperidone ISM®, a new long-acting
      injectable formulation of the licensed drug risperidone, administered in the gluteal muscle
      or the deltoid muscle. Participants were patients with a diagnosis of schizophrenia capable
      of understanding, signing, and consenting to study participation on their own.

      Objectives:

      Primary Objective

      • To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting
      formulation of risperidone over four IM injections in the gluteal and deltoid muscle at 28
      day intervals and at one dose strength (75 mg) in patients with schizophrenia.

      Secondary Objectives

        -  To document the attainment of steady-state exposure by the injectable formulation ISM®
           of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day
           intervals and at one dose strength (75 mg) in patients with schizophrenia.

        -  To perform a descriptive comparison of the PK data between the gluteal and the deltoid
           muscle administration of the injectable formulation ISM® of risperidone over four IM
           injections at 28-day intervals and at one dose strength (75 mg) in patients with
           schizophrenia.

        -  To evaluate the safety and tolerability of the injectable formulation ISM® of
           risperidone after four IM injections in the gluteal muscle or deltoid muscle at 28-day
           intervals at one dose strength (75 mg) in patients with schizophrenia.

      Exploratory Objectives

        -  To explore the efficacy of once every four weeks of the injectable formulation ISM® of
           risperidone after four IM injections in the gluteal muscle or deltoid muscle at 28-day
           (± 1 day) intervals at one dose strength (75 mg) in patients with schizophrenia.

        -  To characterize patients' metabolic phenotype (cytochrome P450 [CYP]2D6, CYP3A4) to
           explain any potential unexpected outlying PK value, and/or explore its relationship with
           any potential safety or tolerability issue.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Plasma Concentration (Cmin) for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve to the Last Quantified Concentration (AUClast) for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve Extrapolated to Infinity (AUC∞) for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
    <description>AUCτ is the area under the curve over the dosing interval (τ), where the dosing interval is 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Concentration (Tmax) for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-life (t1/2) for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PTF for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
    <description>Peak to Trough Fluctuation ratio for the Active Moiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio (RA) for Active Moiety</measure>
    <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
    <description>Defined as AUC (0-28 days) after the 4th dose divided by the AUC (0-28 days) of the first dose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) Total Score</measure>
    <time_frame>Baseline, Days 5, 7, 10, 14, 18, and 21 post Dose 1; Dose 2, 3 and 4 post dose; Days 5, 7, 10, 14, 18, and 21 post Dose 2, 3, and 4; Days 25, 28, 32, 37, 42, 60, 75, 90, and 105 post Dose 4; Day 120 post Dose 4 or early termination.</time_frame>
    <description>The change in PANSS score from Baseline by visit 48.
The PANSS combines 3 subscales: The positive scale (7 items), the negative scale (7 items) and the general psychopathology scale (16 items).
PANSS Items Scores: 1 = Absent, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Moderate Severe, 6 = Severe, 7 = Extreme.
Subscales are summed to compute a total score Range for each of the subscales: Positive scale (7-49); Negative scale (7-49); General psychopathology scale (16-112) Range for the PANSS total scale: 30-210 PANSS total score ≤70: stable schizophrenia PANSS total score between &gt;70: decompensated schizophrenia</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Gluteus (Risperidone ISM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deltoid (Risperdione ISM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone ISM</intervention_name>
    <description>Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.
Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals.</description>
    <arm_group_label>Gluteus (Risperidone ISM)</arm_group_label>
    <arm_group_label>Deltoid (Risperdione ISM)</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable of providing informed consent.

          2. Male or female aged ≥18 years to ≤65 years.

          3. Current diagnosis of schizophrenia, according to Diagnostic and Statistical Manual

          4. Body mass index (BMI) ≥17 kg/m2 but ≤35 kg/m2.

          5. Medically stable over the last month, and psychiatrically stable

          6. On oral stable dosage of risperidone ≥4 mg daily as maintenance therapy.

          7. Total score ≤70 on the Positive and Negative Syndrome Scale.

          8. Using a medically accepted contraceptive method

          9. Agrees to washout all prohibited medications prior to baseline (day -1)

        Exclusion Criteria:

          1. Informed consent obtained from a third party.

          2. Prisoners or patients who are compulsorily detained.

          3. Females who are breast-feeding and/or who have a positive pregnancy test.

          4. Presence of an uncontrolled, unstable clinically significant medical condition.

          5. Positive serology for Hepatitis B, Hepatitis C or anti-HIV 1 and 2 at screening.

          6. History of neuroleptic malignant syndrome.

          7. Current or past history of tardive dyskinesia.

          8. Positive urine drug or alcohol screen finding.

          9. Risk of committing self-harm or harm based on Columbia Suicidal Rating Scale.

         10. Taking more than one antidepressant.

         11. Use of depot antipsychotics within the last three months.

         12. Use of strong or moderate cytochrome P450 isoenzyme 3A4inducers

         13. Use of electroconvulsive therapy (ECT) within the last three months.

         14. Receipt of any investigational drugs within the last three months.

         15. Known or suspected allergy or hypersensitivity to risperidone

         16. Previous non-responder to risperidone treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Llaudó, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Rovi Laboratorios Farmacéuticos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Louis Clinical Trials, LC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <results_first_submitted>October 13, 2016</results_first_submitted>
  <results_first_submitted_qc>June 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gluteus (Risperidone ISM)</title>
          <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
        </group>
        <group group_id="P2">
          <title>Deltoid (Risperdione ISM)</title>
          <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three of the randomized patients (70) were not dosed. Two of them due to withdrawal of consent and the third due to fulfilment of one of the study exclusion criteria (take prohibited medication). Thus, the number of patients receiving the study medication were 67; 34 in the gluteal injection group and 33 in the deltoid injection group.</population>
      <group_list>
        <group group_id="B1">
          <title>Gluteus (Risperidone ISM)</title>
          <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
        </group>
        <group group_id="B2">
          <title>Deltoid (Risperdione ISM)</title>
          <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="11.1"/>
                    <measurement group_id="B2" value="44" spread="9.8"/>
                    <measurement group_id="B3" value="43" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) for Active Moiety</title>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM: Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.
Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM: Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.
Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) for Active Moiety</title>
          <population>The analysis was conducted in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="33.7"/>
                    <measurement group_id="O2" value="54.1" spread="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="52.7"/>
                    <measurement group_id="O2" value="61.0" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="33.3"/>
                    <measurement group_id="O2" value="61.0" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="38.9"/>
                    <measurement group_id="O2" value="57.7" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Plasma Concentration (Cmin) for Active Moiety</title>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentration (Cmin) for Active Moiety</title>
          <population>The analysis was conducted in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="72.6"/>
                    <measurement group_id="O2" value="7.0" spread="87.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.86" spread="90.1"/>
                    <measurement group_id="O2" value="8.60" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.97" spread="70.7"/>
                    <measurement group_id="O2" value="10.2" spread="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="59.1"/>
                    <measurement group_id="O2" value="9.52" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve to the Last Quantified Concentration (AUClast) for Active Moiety</title>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 18 patients in the gluteal and 22 in the deltoids had concentration amenable to evaluation..</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve to the Last Quantified Concentration (AUClast) for Active Moiety</title>
          <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 18 patients in the gluteal and 22 in the deltoids had concentration amenable to evaluation..</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21300" spread="35.2"/>
                    <measurement group_id="O2" value="23300" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve Extrapolated to Infinity (AUC∞) for Active Moiety</title>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 11 patients in the gluteal and 18 in the deltoids had concentration amenable to evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Extrapolated to Infinity (AUC∞) for Active Moiety</title>
          <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 11 patients in the gluteal and 18 in the deltoids had concentration amenable to evaluation.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21100" spread="27.4"/>
                    <measurement group_id="O2" value="22700" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCτ for Active Moiety</title>
        <description>AUCτ is the area under the curve over the dosing interval (τ), where the dosing interval is 28 days</description>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population: 43 patients (20 in the gluteal and 23 in the deltoid site injection group). As determined by the pharmacokineticist, for Dose 4th analysis, 18 patients in the gluteal and 22 in the deltoid group had concentration amenable to evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ for Active Moiety</title>
          <description>AUCτ is the area under the curve over the dosing interval (τ), where the dosing interval is 28 days</description>
          <population>The analysis was conducted in the PK population: 43 patients (20 in the gluteal and 23 in the deltoid site injection group). As determined by the pharmacokineticist, for Dose 4th analysis, 18 patients in the gluteal and 22 in the deltoid group had concentration amenable to evaluation.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14100" spread="39.5"/>
                    <measurement group_id="O2" value="16300" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15400" spread="59.3"/>
                    <measurement group_id="O2" value="18000" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16600" spread="24.2"/>
                    <measurement group_id="O2" value="18200" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17300" spread="27.1"/>
                    <measurement group_id="O2" value="18500" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Peak Concentration (Tmax) for Active Moiety</title>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Concentration (Tmax) for Active Moiety</title>
          <population>The analysis was conducted in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="23.9" upper_limit="504"/>
                    <measurement group_id="O2" value="48.0" lower_limit="23.8" upper_limit="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="2.0" upper_limit="48.1"/>
                    <measurement group_id="O2" value="24.0" lower_limit="2.08" upper_limit="479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="12.0" upper_limit="504"/>
                    <measurement group_id="O2" value="24.0" lower_limit="2.0" upper_limit="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="7.97" upper_limit="502"/>
                    <measurement group_id="O2" value="48.0" lower_limit="2.13" upper_limit="505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-life (t1/2) for Active Moiety</title>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 12 patients in the gluteal and 19 in the deltoid group had concentration amenable to evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2) for Active Moiety</title>
          <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 12 patients in the gluteal and 19 in the deltoid group had concentration amenable to evaluation.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" spread="80.5"/>
                    <measurement group_id="O2" value="269" spread="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PTF for Active Moiety</title>
        <description>Peak to Trough Fluctuation ratio for the Active Moiety</description>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conduct in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>PTF for Active Moiety</title>
          <description>Peak to Trough Fluctuation ratio for the Active Moiety</description>
          <population>The analysis was conduct in the PK population, which includes 43 patients (20 in the gluteal and 23 in the deltoid site injection group) who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis. They also had concentration data amenable to evaluation as determined by the pharmacokineticist.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.999" spread="181.6"/>
                    <measurement group_id="O2" value="1.76" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="38.1"/>
                    <measurement group_id="O2" value="1.88" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="51.9"/>
                    <measurement group_id="O2" value="1.82" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio (RA) for Active Moiety</title>
        <description>Defined as AUC (0-28 days) after the 4th dose divided by the AUC (0-28 days) of the first dose.</description>
        <time_frame>Dose 1, 2 and 3: Pre-dose; at 2, 8, 12, 24 and 48 hours post-dose; 5, 7, 10, 14, 18, and 21 days post-dose. Dose 4: Pre dose; at 2, 8, 12, 24, and 48 hours post-dose; at 5, 7, 10, 14, 18, 21, 25, 28, 32, 37, 42, 60, 75, 90, 105, and 120 days post-dose.</time_frame>
        <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 18 patients in the gluteal and 22 in the deltoid group had concentration amenable to evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio (RA) for Active Moiety</title>
          <description>Defined as AUC (0-28 days) after the 4th dose divided by the AUC (0-28 days) of the first dose.</description>
          <population>The analysis was conducted in the PK population (patients who had at least 1 PK sample taken and had no major protocol deviations that would exclude them from PK analysis). As determined by the pharmacokineticist, for this analysis, 18 patients in the gluteal and 22 in the deltoid group had concentration amenable to evaluation.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="25.1"/>
                    <measurement group_id="O2" value="1.14" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Positive and Negative Syndrome Scale (PANSS) Total Score</title>
        <description>The change in PANSS score from Baseline by visit 48.
The PANSS combines 3 subscales: The positive scale (7 items), the negative scale (7 items) and the general psychopathology scale (16 items).
PANSS Items Scores: 1 = Absent, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Moderate Severe, 6 = Severe, 7 = Extreme.
Subscales are summed to compute a total score Range for each of the subscales: Positive scale (7-49); Negative scale (7-49); General psychopathology scale (16-112) Range for the PANSS total scale: 30-210 PANSS total score ≤70: stable schizophrenia PANSS total score between &gt;70: decompensated schizophrenia</description>
        <time_frame>Baseline, Days 5, 7, 10, 14, 18, and 21 post Dose 1; Dose 2, 3 and 4 post dose; Days 5, 7, 10, 14, 18, and 21 post Dose 2, 3, and 4; Days 25, 28, 32, 37, 42, 60, 75, 90, and 105 post Dose 4; Day 120 post Dose 4 or early termination.</time_frame>
        <population>The analysis was conduct in the Intent-to-Treat (ITT) Population, which includes all patients in Safety Population with baseline (Day -1) efficacy data and at least 1 post-baseline efficacy evaluation. ITT Population includes 66 patients; 33 on each arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Gluteus (Risperidone ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
          </group>
          <group group_id="O2">
            <title>Deltoid (Risperdione ISM)</title>
            <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Syndrome Scale (PANSS) Total Score</title>
          <description>The change in PANSS score from Baseline by visit 48.
The PANSS combines 3 subscales: The positive scale (7 items), the negative scale (7 items) and the general psychopathology scale (16 items).
PANSS Items Scores: 1 = Absent, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Moderate Severe, 6 = Severe, 7 = Extreme.
Subscales are summed to compute a total score Range for each of the subscales: Positive scale (7-49); Negative scale (7-49); General psychopathology scale (16-112) Range for the PANSS total scale: 30-210 PANSS total score ≤70: stable schizophrenia PANSS total score between &gt;70: decompensated schizophrenia</description>
          <population>The analysis was conduct in the Intent-to-Treat (ITT) Population, which includes all patients in Safety Population with baseline (Day -1) efficacy data and at least 1 post-baseline efficacy evaluation. ITT Population includes 66 patients; 33 on each arm.</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day -1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" spread="10.4"/>
                    <measurement group_id="O2" value="60" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 48 (Day 120 post Dose 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" spread="16.4"/>
                    <measurement group_id="O2" value="61" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected in all visits of the study: Screening, Baseline (Day -1); Day 0 (Dose 1); Days 1, 2, 5, 7, 10, 14, 18 &amp; 21 Post Dose 1; Dose 2, 3 &amp; 4 Prior to Dosage and Post Dose; Days 1, 2, 5, 7, 10, 14, 18 &amp; 21 Post Dose 2, 3 &amp; 4; Days 25, 28, 32, 37, 42, 60, 75, 90 &amp; 105 Post-Dose 4; Day 120 Post-Dose 4 (final visit) or any Early Termination.</time_frame>
      <desc>The analysis was performed in the Safety Population, which includes all patients who received at least 1 dose of the study drug: 67 patients in total, 34 of them were in the gluteal arm and 33 in the Deltoid arm. This is the population at risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gluteus (Risperidone ISM)</title>
          <description>Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
Risperidone ISM</description>
        </group>
        <group group_id="E2">
          <title>Deltoid (Risperdione ISM)</title>
          <description>Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
Risperidone ISM</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (17.0)">Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (17.0)">Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Oromandibular dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperprolactinaemia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="19" subjects_at_risk="34"/>
                <counts group_id="E2" events="41" subjects_affected="17" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E2" events="25" subjects_affected="10" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal stiffness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Drooling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Oromandibular dystonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor intends to publish clinical data from all centers participating in the investigation. A draft manuscripts will submit to all participating investigators for their comments. Individual investigators subsequently may publish additional findings of this study in scientific journals/scientific meetings, provided that the sponsor is given ample opportunity to review any proposed abstract, manuscript, or slide presentation prior to its submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jordi Llaudó Garín ( Clinical Development Manager)</name_or_title>
      <organization>Rovi S.A. Laboratorios Farmacéuticos</organization>
      <phone>+34913756230</phone>
      <email>jllaudo@rovi.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

